SCHEMBL19284356

SCHEMBL19284356

Cn1cc(-c2ncc(C(=O)O)n2CC2CC2)cn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PADI4 Q9UM07 2/20 0.41
▸ NOTUM Q6P988 1/20 0.41
▸ GSK3B P49841 5/20 0.38
▸ DYRK1A Q13627 5/20 0.38
▸ WNT1 P04628 4/20 0.38
▸ PIM1 P11309 1/20 0.38
▸ PIM2 Q9P1W9 1/20 0.38
▸ CHEK1 O14757 1/20 0.37
▸ CLK1 P49759 2/20 0.37
▸ MAP4K4 O95819 1/20 0.36
▸ FGFR1 P11362 1/20 0.35
▸ FGFR2 P21802 1/20 0.35
▸ FGFR4 P22455 1/20 0.35
▸ FGFR3 P22607 1/20 0.35
▸ KDR P35968 1/20 0.35
▸ BRD4 O60885 1/20 0.35
▸ EP300 Q09472 1/20 0.35
▸ CREBBP Q92793 1/20 0.35
▸ JAK2 O60674 1/20 0.35
▸ JAK3 P52333 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19284323 0.85 PADI4 (0.39) PADI4GSK3BDYRK1AWNT1CLK1
SCHEMBL27757298 0.82 NOTUM (0.43) NOTUM
SCHEMBL19301805 0.81 PADI4 (0.39) PADI4NOTUMGSK3BDYRK1AWNT1
SCHEMBL23566053 0.79 PADI4 (0.38) PADI4GSK3BDYRK1AWNT1FGFR1
SCHEMBL19284354 0.73 LMNA (0.45) PADI4
SCHEMBL19301796 0.71 PADI4 (0.42) PADI4NOTUM
SCHEMBL4026878 0.66 NOTUM (0.42) NOTUMBRD4
SCHEMBL28533742 0.66 NOTUM (0.43) NOTUMBRD4CREBBP
SCHEMBL28531220 0.66 NOTUM (0.43) NOTUMBRD4
SCHEMBL19301627 0.63 KDM4E (0.43) PADI4NOTUMCHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11897866-B2 Heteroaryl inhibitors of PAD4 PADLOCK THERAPEUTICS, INC. (US) 2024-02-13 — — US disclosed
US-20220081418-A1 HETEROARYL INHIBITORS OF PAD4 PADLOCK THERAPEUTICS INC (US) 2022-03-17 — — US disclosed
US-11198681-B2 Heteroaryl inhibitors of PAD4 PADLOCK THERAPEUTICS, INC. (US) 2021-12-14 — — US disclosed
US-11198681-B2 Heteroaryl inhibitors of PAD4 PADLOCK THERAPEUTICS, INC. (US) 2021-12-14 — — US disclosed
CN-109071497-B PAD4 heteroaryl inhibitors 帕德罗科治疗公司 2021-10-22 — — CN disclosed
US-20210188810-A1 HETEROARYL INHIBITORS OF PAD4 PADLOCK THERAPEUTICS INC (US) 2021-06-24 — — US disclosed
US-20210188810-A1 HETEROARYL INHIBITORS OF PAD4 PADLOCK THERAPEUTICS INC (US) 2021-06-24 — — US disclosed
EP-3419969-A1 HETEROARYL INHIBITORS OF PAD4 Padlock Therapeutics, Inc. (US) 2019-01-02 — — EP disclosed
WO-2017147102-A1 HETEROARYL INHIBITORS OF PAD4 PADLOCK THERAPEUTICS, INC. (US) 2017-08-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210188810-A1 HETEROARYL INHIBITORS OF PAD4 PADI4, PADI1, PADI6 PADI4 1/4885NOTUM 1117/4885GSK3B 271/4885
US-11897866-B2 Heteroaryl inhibitors of PAD4 PADI4, PADI1, PADI6 PADI4 1/4885NOTUM 1117/4885GSK3B 271/4885
US-20220081418-A1 HETEROARYL INHIBITORS OF PAD4 PADI4, PADI1, PADI6 PADI4 1/4885NOTUM 1117/4885GSK3B 271/4885
US-11198681-B2 Heteroaryl inhibitors of PAD4 PADI4, PADI1, PADI6 PADI4 1/4885NOTUM 1117/4885GSK3B 271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback